About
Titles
Assistant Professor Adjunct
Research
Publications
2024
Effective immunosurveillance of clonally expanded mammary aneuploid cells
Galluzzi L, Manic G, Vitale I. Effective immunosurveillance of clonally expanded mammary aneuploid cells. Cellular & Molecular Immunology 2024, 1-3. PMID: 39668162, DOI: 10.1038/s41423-024-01250-x.Peer-Reviewed Original ResearchImpact of radiotherapy dose, fractionation and immunotherapeutic partner in a mouse model of HR+ mammary carcinogenesis
Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B, Guarracino A, Rippon B, Beltran-Visiedo M, Soler-Agesta R, Pannellini T, Fucikova J, Demaria S, Zhou X, Elemento O, Formenti S, Galluzzi L. Impact of radiotherapy dose, fractionation and immunotherapeutic partner in a mouse model of HR+ mammary carcinogenesis. Journal Of The National Cancer Institute 2024, djae329. PMID: 39661487, DOI: 10.1093/jnci/djae329.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRadiation therapyFocal RTOverall survivalMammary carcinogenesisPD-1Impact of radiotherapy doseMouse modelPD-1 blockerRT plus immunotherapyPrimary tumor growthPrimary disease controlIncrease local controlCheckpoint inhibitorsRadiotherapy doseHypofractionated RTOS benefitTumor burdenPrimary tumorBreast cancerTumor growthNeoplastic lesionsLocal controlICI sensitivityEffective immunityImmunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Catanzaro E, Beltrán-Visiedo M, Galluzzi L, Krysko D. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cellular & Molecular Immunology 2024, 1-16. PMID: 39653769, DOI: 10.1038/s41423-024-01245-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmunogenic cell deathImmunogenic cell death inducerCheckpoint inhibitorsRefractory to immune checkpoint inhibitorsImmunogenicity of cell deathFraction of patientsCombinatorial treatment strategiesAdaptive immune responsesCell deathCombinatorial partnersCancer immunotherapyCombinatorial regimensClinical findingsClinical managementTreatment strategiesClinical activityImmune responseImmunotherapyPatientsCancerOncology settingInhibitorsDeathInducerTargeting mitophagy to maximize the immunostimulatory effects of radiation therapy in ER+ breast cancer
Guilbaud E, Sato A, Yamazaki T, Galluzzi L. Targeting mitophagy to maximize the immunostimulatory effects of radiation therapy in ER+ breast cancer. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2024, 1870: 167381. DOI: 10.1016/j.bbadis.2024.167381.Peer-Reviewed Original Research777 Mitochondrial involvement in the cytotoxicity and immunogenicity of radiation therapy
Visiedo M, Agesta R, Guilbaud E, Sato A, Galluzzi L. 777 Mitochondrial involvement in the cytotoxicity and immunogenicity of radiation therapy. 2024, a881-a881. DOI: 10.1136/jitc-2024-sitc2024.0777.Peer-Reviewed Original ResearchThe hallmarks of cancer immune evasion
Galassi C, Chan T, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell 2024, 42: 1825-1863. PMID: 39393356, DOI: 10.1016/j.ccell.2024.09.010.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCancer immune evasionHost immune systemImmune evasionNeoplastic cellsImmune systemImmune effector cellsConventional therapeutic strategiesModern immunotherapyAnticancer immunosurveillanceEffector cellsImmune escapeImmunoevasion mechanismsMalignant cellsMicroscopic neoplasmsCancer outgrowthImmune cytotoxicityImmune recognitionTherapeutic strategiesEpigenetic alterationsCancer cellsCell precursorsCancerCellsHallmarksImmunotherapyPrognostic value of atypical B cells in breast cancer
García-Torralba E, Galluzzi L, Buqué A. Prognostic value of atypical B cells in breast cancer. Trends In Cancer 2024, 10: 990-991. PMID: 39353814, DOI: 10.1016/j.trecan.2024.09.009.Peer-Reviewed Original ResearchAltmetricEpigenetic control of immunoevasion in cancer stem cells
Galassi C, Esteller M, Vitale I, Galluzzi L. Epigenetic control of immunoevasion in cancer stem cells. Trends In Cancer 2024, 10: 1052-1071. PMID: 39244477, DOI: 10.1016/j.trecan.2024.08.004.Peer-Reviewed Original ResearchAltmetricConceptsCancer stem cellsTumor-targeting immune responsesPopulation of malignant cellsStem cellsResistance to therapyStages of cancer progressionHost immune systemDisease relapseMalignant cellsTumor progressionImmune recognitionNeoplastic cellsImmune responseCancer progressionImmune systemEvade recognitionEpigenetic modification of DNATherapeutic targetCancerEpigenetic modificationsCellsEpigenetic controlModification of DNAImmunotherapyMalignancyMetabolic regulation of the mitochondrial immune checkpoint
Montrose D, Saha S, Galluzzi L. Metabolic regulation of the mitochondrial immune checkpoint. OncoImmunology 2024, 13: 2394247. PMID: 39206097, PMCID: PMC11352702, DOI: 10.1080/2162402x.2024.2394247.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTumor-targeting immune responsesColorectal cancer cellsAnticancer immunityImmune checkpointsActivation of cGASMalignant cellsImmune responseCancer cellsDisrupt mitochondrial functionAccumulation of mitochondrial DNACytosolic accumulationMitochondrial dysfunctionMetabolic regulationMitochondrial DNAMitochondrial functionSerine resultsCellsDysfunctionChemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, Griebler H, Drozenova J, Mojzisova K, Vankerckhoven A, Laco J, Ryška A, Dundr P, Kocian R, Cibula D, Brtnicky T, Skapa P, Jacob F, Kovar M, Praznovec I, McNeish I, Halaska M, Rob L, Coosemans A, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer. Clinical Cancer Research 2024, of1-of17. PMID: 39163092, DOI: 10.1158/1078-0432.ccr-24-1594.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHigh-grade serous ovarian carcinomaImmune checkpoint inhibitorsTertiary lymphoid structuresT cellsLymphoid structuresRecruitment of immune effector cellsMature tertiary lymphoid structuresCD8+ T cellsMetastatic ovarian cancerT-cell phenotypeFollicular T cellsSerous ovarian carcinomaSignificant survival benefitNeo-adjuvant chemotherapyImmune effector cellsIndependent patient cohortTargeted anticancer agentsCombinatorial partnersTesting chemotherapyCheckpoint inhibitorsTfh cellsCalreticulin exposureOvarian carcinomaPaclitaxel-carboplatinSyngeneic model